NCT05119790View on ClinicalTrials.gov

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

November 5, 2021

Study Completion Date

November 5, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

[14C] BIIB122 ([14C] DNL151)

Oral dose

Trial Locations (1)

21201

Pharmaron CPC, Baltimore

Sponsors

Lead Sponsor

Biogen

Collaborators (1)

Denali Therapeutics Inc.
All Listed Sponsors
collaborator

Denali Therapeutics Inc.

INDUSTRY

lead

Biogen

INDUSTRY

NCT05119790 - A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter